“Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)”

//“Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)”

“Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)”

At ISPOR Europe 2022, Omakase presented the POSTER “Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)” in collaboration with a multidisciplinary expert group including clinicians, pharmacists, patient representative and supported by Sanofi.
Olipudase got one of the highest scores on the rare disease MCDA meaning that was perceived as a high value drug.

 

2024-04-02T10:30:41+00:00November 24th, 2022|Abstracts/posters|